NVS vs PTCT
NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases. PTCT: A commercial-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for rare genetic diseases.
Side-by-side fundamentals
| Metric | NVS | PTCT | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $156.11 | $68.01 | |
| Market cap as of 2026-08-03 | $232.1B | $5.7B | |
| P/E as of 2026-08-03 | 22.53 | n/a | |
| PEG as of 2026-08-03 | 3.66 | 0.86 | PTCT lower |
| Net margin as of 2026-08-03 | +22.5% | -14.5% | NVS higher |
| Gross margin as of 2026-08-03 | +75.0% | +73.2% | NVS higher |
| Operating margin as of 2026-08-03 | +29.9% | -1.6% | NVS higher |
| ROE as of 2026-08-03 | +29.9% | -351.9% | NVS higher |
| ROA as of 2026-08-03 | +11.1% | -4.3% | NVS higher |
| Debt / equity as of 2026-08-03 | 1.18 | 848.93 | NVS lower |
| Revenue growth (YoY) as of 2026-08-03 | +3.3% | -53.3% | NVS higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +35.3% | |
| Dividend yield as of 2026-08-03 | +2.9% | n/a | |
| Beta as of 2026-08-03 | 1.17 | 0.98 | |
| 1-year return as of 2026-07-27 close | +32.6% | +30.5% | NVS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.